Research: Liver physiology, pathology and molecular signatures. Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in North America and can lead to Type II diabetes, liver cirrhosis (requiring liver transplantation), liver cancer (hepatocellular cancer, ) and increase the probability of other types of cancer spreading to the liver (liver metastasis). With the help of our human tissue bank and technologies such as proteomics and genomics, we hope to find new therapies for these diseases
Expertise: liver metastasis; liver ischemia/reperfusion injury; non-alcoholic liver disease; hepatocellullar carcinoma; neuroendocrine tumors; proteomics; tissue banking
Research: Over 26 years research experience, with a focus on translational cancer research
Expertise: Molecular and cellular biology, academic (over 16 years) and industry (10 years) experience, project management, and biobanking
Research: Manage the Liver Disease Biobank, Oversee all immunohistochemistry and immunofluorescence methodology in the lab. Research of vascularity in colorectal cancer liver metastases and other types of liver diseases (Hepatocellular carcinoma, cholangio carcinoma, Nonalcoholic fatty liver disease and Nonalcoholic steatohepatitis)
Expertise: Biobanking (Ethics, sample procurement, processing and clinical data/annotation), Project management, SOP development, Immunohistochemistry and immunofluorescence, GCP (Good clinical practice), Histology
Research: To identify the molecular mechanisms by which tumor cells interact with their environment to acquire anti-angiogenic therapy resistance in colorectal cancer liver metastases (CRCLM). Ultimately I hope to find a novel biomarker guided targeted therapy to block tumor metastases and chemoresistance
Expertise: Characterisation of novel post-translational modulators of p53 in various cancers. Inhibitor Apoptosis Proteins (IAPs) and fatty acid beta oxidation genes as the key regulators of ovarian cancer cisplatin resistance
Research: Investigate the role of neutrophils infiltrating colorectal cancer liver metastases (CRCLM) and their influence on the development of a replacement or desmoplastic growth pattern
Expertise: Signalling pathways and transcription factors regulating neutrophil functions namely cytokine production
Research: AI-powered multi-omic signature discovery for precision care of patients with Colorectal Cancer Liver Metastases (CRCLM). The goal of this project is to optimise the current cancer treatment strategy and contribute towards the personalised therapeutic approach in treating cancer
Expertise: Recombinant DNA technology, RT-PCR, gel electrophoresis, Site directed mutagenesis, cell culture techniques and transmission genetics
Research: Current project focuses on understanding the interplay between immunoactive and angiogenic factors in primary liver cancer (Hepatocellular carcinoma).
Other research interest is focused on understanding the concurrent expression and epigenetic changes that occur in tumor cells that promote metastatic colorectal liver cancer (mCRC) disease progression.
Expertise: Molecular biology including tissue processing, murine work, DNA gel extraction and quantification, western blots, PCR, qPCR, light and fluorescence microscopy.
Bioinformatics including analysis of biological data, application of statistics in the context of biology and genomics, DNAseq, RNAseq, ATACseq, functional genomics, and expertise in common bioinformatic software.
Nisreen Ibrahim (PhD)
Diane Kim (MSc)
Vincent Palmieri (MSc)
Flemming Kundrop (Honours)
George Jarrouj (Honours)